NCT00075439View on ClinicalTrials.gov

Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

May 31, 2007

Conditions
GastrinomaGlucagonomaInsulinomaMetastatic Gastrointestinal Carcinoid TumorPancreatic Polypeptide TumorRecurrent Gastrointestinal Carcinoid TumorRecurrent Islet Cell CarcinomaSomatostatinomaWDHA Syndrome
Interventions
DRUG

gefitinib

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

55905

Mayo Clinic, Rochester

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00075439 - Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter